Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health
There is now strong evidence to support the interest in using lactic acid bacteria (LAB)in particular, strains of lactococci and lactobacilli, as well as bifidobacteria, for the development of new live vectors for human and animal health purposes. LAB are Gram-positive bacteria that have been used f...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2110821 |
| _version_ | 1811216243777077248 |
|---|---|
| author | Romina Levit Naima G. Cortes-Perez Alejandra de Moreno de Leblanc Jade Loiseau Anne Aucouturier Philippe Langella Jean Guy LeBlanc Luis G. Bermúdez-Humarán |
| author_facet | Romina Levit Naima G. Cortes-Perez Alejandra de Moreno de Leblanc Jade Loiseau Anne Aucouturier Philippe Langella Jean Guy LeBlanc Luis G. Bermúdez-Humarán |
| author_sort | Romina Levit |
| collection | DOAJ |
| description | There is now strong evidence to support the interest in using lactic acid bacteria (LAB)in particular, strains of lactococci and lactobacilli, as well as bifidobacteria, for the development of new live vectors for human and animal health purposes. LAB are Gram-positive bacteria that have been used for millennia in the production of fermented foods. In addition, numerous studies have shown that genetically modified LAB and bifodobacteria can induce a systemic and mucosal immune response against certain antigens when administered mucosally. They are therefore good candidates for the development of new mucosal delivery strategies and are attractive alternatives to vaccines based on attenuated pathogenic bacteria whose use presents health risks. This article reviews the most recent research and advances in the use of LAB and bifidobacteria as live delivery vectors for human and animal health. |
| first_indexed | 2024-04-12T06:36:09Z |
| format | Article |
| id | doaj.art-a68254227aaa4398894b9cf5b8c892b9 |
| institution | Directory Open Access Journal |
| issn | 1949-0976 1949-0984 |
| language | English |
| last_indexed | 2024-04-12T06:36:09Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj.art-a68254227aaa4398894b9cf5b8c892b92022-12-22T03:43:52ZengTaylor & Francis GroupGut Microbes1949-09761949-09842022-12-0114110.1080/19490976.2022.2110821Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal healthRomina Levit0Naima G. Cortes-Perez1Alejandra de Moreno de Leblanc2Jade Loiseau3Anne Aucouturier4Philippe Langella5Jean Guy LeBlanc6Luis G. Bermúdez-Humarán7Centro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145, (T4000ILC) San Miguel de Tucumán, Tucumán, ArgentinaUniversité Paris-Saclay, INRAE, AgroParisTech, UMR 0496, 78350 Jouy-en-Josas, FranceCentro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145, (T4000ILC) San Miguel de Tucumán, Tucumán, ArgentinaMicalis Institute, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, FranceMicalis Institute, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, FranceMicalis Institute, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, FranceCentro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145, (T4000ILC) San Miguel de Tucumán, Tucumán, ArgentinaMicalis Institute, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, FranceThere is now strong evidence to support the interest in using lactic acid bacteria (LAB)in particular, strains of lactococci and lactobacilli, as well as bifidobacteria, for the development of new live vectors for human and animal health purposes. LAB are Gram-positive bacteria that have been used for millennia in the production of fermented foods. In addition, numerous studies have shown that genetically modified LAB and bifodobacteria can induce a systemic and mucosal immune response against certain antigens when administered mucosally. They are therefore good candidates for the development of new mucosal delivery strategies and are attractive alternatives to vaccines based on attenuated pathogenic bacteria whose use presents health risks. This article reviews the most recent research and advances in the use of LAB and bifidobacteria as live delivery vectors for human and animal health.https://www.tandfonline.com/doi/10.1080/19490976.2022.2110821Lactic acid bacterialactococcus lactislactobacillus sppbifidobacterialive delivery vectorsmucosal vaccines |
| spellingShingle | Romina Levit Naima G. Cortes-Perez Alejandra de Moreno de Leblanc Jade Loiseau Anne Aucouturier Philippe Langella Jean Guy LeBlanc Luis G. Bermúdez-Humarán Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health Gut Microbes Lactic acid bacteria lactococcus lactis lactobacillus spp bifidobacteria live delivery vectors mucosal vaccines |
| title | Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health |
| title_full | Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health |
| title_fullStr | Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health |
| title_full_unstemmed | Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health |
| title_short | Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health |
| title_sort | use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health |
| topic | Lactic acid bacteria lactococcus lactis lactobacillus spp bifidobacteria live delivery vectors mucosal vaccines |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2022.2110821 |
| work_keys_str_mv | AT rominalevit useofgeneticallymodifiedlacticacidbacteriaandbifidobacteriaaslivedeliveryvectorsforhumanandanimalhealth AT naimagcortesperez useofgeneticallymodifiedlacticacidbacteriaandbifidobacteriaaslivedeliveryvectorsforhumanandanimalhealth AT alejandrademorenodeleblanc useofgeneticallymodifiedlacticacidbacteriaandbifidobacteriaaslivedeliveryvectorsforhumanandanimalhealth AT jadeloiseau useofgeneticallymodifiedlacticacidbacteriaandbifidobacteriaaslivedeliveryvectorsforhumanandanimalhealth AT anneaucouturier useofgeneticallymodifiedlacticacidbacteriaandbifidobacteriaaslivedeliveryvectorsforhumanandanimalhealth AT philippelangella useofgeneticallymodifiedlacticacidbacteriaandbifidobacteriaaslivedeliveryvectorsforhumanandanimalhealth AT jeanguyleblanc useofgeneticallymodifiedlacticacidbacteriaandbifidobacteriaaslivedeliveryvectorsforhumanandanimalhealth AT luisgbermudezhumaran useofgeneticallymodifiedlacticacidbacteriaandbifidobacteriaaslivedeliveryvectorsforhumanandanimalhealth |